

Disclosures

Personal Commercial (40)

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|---|---|--------------------------|--|
| <i>Self</i> | | | |
| Abbott Laboratories | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| American Regent | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Amgen | Data Safety Monitoring Board | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Applied Therapeutics | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| AstraZeneca Pharmaceuticals | Consultant Fees/Honoraria | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Bayer | Consultant Fees/Honoraria | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Boehringer Ingelheim Pharmaceuticals, Inc | Consultant Fees/Honoraria | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Bristol-Myers Squibb Company | Data Safety Monitoring Board | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Cardiac Dimension | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Cardior | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| CVRx | Consultant Fees/Honoraria | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Cytokinetics | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Daxor | Consultant Fees/Honoraria | None (\$0) | Heart Failure and Cardiomyopathies |
| Edwards | Consultant Fees/Honoraria | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Element Sciences | Consultant Fees/Honoraria | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Eli Lilly and Company | Consultant Fees/Honoraria | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| FIRE1 | Consultant Fees/Honoraria | None (\$0) | Heart Failure and Cardiomyopathies |
| G3 Pharmaceutical | Other - <i>Shares</i> | None (\$0) | Heart Failure and Cardiomyopathies |
| Imbira | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Impulse Dynamics | Consultant Fees/Honoraria | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Innolife | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Inventiva | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Lexicon | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| LivaNova | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Medscape | Other - <i>Medscape on line CME teaching programs</i> | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Medtronic | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Merck & Co., Inc. | Consultant Fees/Honoraria | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Novartis | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Novartis Corporation | Speaker's Bureau | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Novo Nordisk Inc. | Consultant Fees/Honoraria | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| Occlutech | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Pfizer | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Pharmacosmos | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Pharmaln | Stock | None (\$0) | Heart Failure and Cardiomyopathies |
| Roche | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |

| Company Name | Relationship Category | Compensation Level | Topic Area(s) |
|---------------|---------------------------|--------------------------|------------------------------------|
| Sequanna | Consultant Fees/Honoraria | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |
| SQ Innovation | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Tenex | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Tricog | Consultant Fees/Honoraria | Modest (< \$5,000) | Heart Failure and Cardiomyopathies |
| Vifor | Consultant Fees/Honoraria | Significant (>= \$5,000) | Heart Failure and Cardiomyopathies |

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (6)

| Non-Commercial Entity Name | Relationship Category | Compensation Level | Topic Area(s) |
|---|---|--------------------------|------------------------------------|
| Self | | | |
| Cardiometabolic Centers Alliance | Officer, Director, Trustee, or other Fiduciary Role | None (\$0) | Prevention |
| Circulation | Other - Editorial Board | None (\$0) | Heart Failure and Cardiomyopathies |
| European Heart Journal | Other - Editorial board | None (\$0) | Heart Failure and Cardiomyopathies |
| European Journal of Heart Failure | Other - Associate Editor | None (\$0) | Heart Failure and Cardiomyopathies |
| JACC Heart Failure | Other - Editorial Board | None (\$0) | Heart Failure and Cardiomyopathies |
| Journal of the American College of Cardiology | Other - Guest Editor in Chief | Significant (>= \$5,000) | Other |

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 1/9/2024
URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

Confidentiality, Disclosure and Assignment Agreement | Signed on 1/9/2024
URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

Embargo | Signed on 1/9/2024
URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

On-Going Obligation Agreement | Signed on 1/9/2024

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.